Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

The Lancet Respiratory Medicine in conversation with
25/10/2024 10 min
Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

Listen "Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)"

Descargar episodio

Episode Synopsis

Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

More episodes of the podcast The Lancet Respiratory Medicine in conversation with

Finn McQuaid and Matthew Saunders on Tuberculosis and Climate change 30/10/2025
Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis 28/09/2025
Guy Brusselle and Celeste Porsbjerg on State-of-the-art insights into prevention, development, and management of asthma 28/09/2025
Joan Soriano on Global Epidemiology of Respiratory Disease 17/07/2025
Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial 16/07/2025
Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian) 16/07/2025
Laura Garriga-Grimau on bronchiectasis in children and young people 02/07/2025
Marcus J Schultz and Prashant Nasa on defining and subphenotyping ARDS 04/06/2025
Hjalmar Bouma on sepsis in patients who are immunocompromised 20/05/2025
Simon Wolf on pulmonary embolism in children and adolescents in the US during 2016 and 2019 07/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA